Almirall, a global biopharmaceutical company dedicated to medical dermatology, this weekend hosted the 17th edition of Skin ...

As the 2026 American Academy of Dermatology (AAD) annual meeting approaches, MedPage Today is offering a preview of an ...

Roflumilast cream 0.05% was well-tolerated and effective for the long-term treatment of mild to moderate atopic dermatitis in ...

Many eczema patients skip the mental health talk. Learn how to discuss anxiety and depression with your dermatologist to unlock better treatment options and systemic therapies.

Children with moderate to severe atopic dermatitis had improved skin barrier function with 16-week dupilumab treatment in both lesional and nonlesional skin, according to data published in Annals of ...

APEX Part A data demonstrated durable maintenance of response at 52-weeks for every 3- and 6-months dosing, respectively, including: - 75% and 85% patients maintained EASI-75 - 86 ...

A topic dermatitis is a chronic condition that tends to rear its itchy head during certain periods before subsiding — for months, possibly, or even years. It particularly affects the insides of the ...

Apogee Therapeutics shares rally as Phase 2 APEX data show durable atopic dermatitis control with 3- or 6-month dosing.

Almirall, S.A. (ALM), a global biopharmaceutical company focused on medical dermatology, today announced positive, top-line ...

If none of your atopic dermatitis treatments have worked, you may be experiencing burnout (or treatment fatigue). Here's what to do next.

IRVINGTON, VA, UNITED STATES, March 19, 2026 /EINPresswire.com/ — The Dermatology Education Foundation today announced the launch of the Access Granted(TM) Initiative, a compreh ...

LONG BEACH, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, ...